Associate Professor and Vice Chair of Research, Desai Sethi Urology Institute
Co-Chair of Genitourinary Site Disease Group, Sylvester Comprehensive Cancer Center University of Miami Leonard M. Miller School of Medicine
Biography
Dr. Punnen is a board-certified urologist with specialized training in oncology. He completed medical school at Queen’s Health Science and a residency in urology at the University of Toronto in Canada. He then completed a fellowship in uro-oncology at the University of California, San Francisco, where he attained a master’s degree in clinical research. He treats prostate cancer, bladder cancer, and kidney cancer and is an expert in robotic surgery. Dr. Punnen also has expertise in using MRI and biomarkers for prostate cancer evaluation and performing MRI-guided and transperineal biopsies of the prostate.Dr. Punnen does a significant amount of research and is lead investigator of several cancer trials at Desai Sethi Urology Institute, University of Miami Leonard M. Miller School of Medicine.
Education & Training
Education
2013: University of California, San Francisco , San Francisco, California
Other, Master’s of Advanced Sciences in Clinical Research
2005: Queen's University, Kingston, Ontario
MD, Medicine
2000: University of Western Ontario, London, Ontario
BS, Honors Bachelor of Science, Physiology
Post Graduate Training
2013: University of California, San Francisco, San Francisco, California
Fellowship, Uro-Oncology
2010: University of Toronto
Residency, Urology
Licensures and Certifications
American Board of Urology
FLDOH
FL Department of Health
Drug Enforcement Agency
CA Department of Health
Royal College of Physicians and Surgeons of Canada
Honors & Awards
No result found
Research Interests
Dr. Punnen's research interest is in prostate cancer, primarily related to imaging, genomic, and molecular biomarkers in the detection, risk stratification, and monitoring of prostate cancer. Dr. Punnen is a lead investigator on two prospective clinical trials validating a novel blood-based biomarker called the 4KScore test for predicting the risk of clinically significant prostate cancer and need for biopsy of the prostate. He is also the Principal Investigator on an ongoing NCI funded prospective clinical trial examining the impact of prostate MRI and tissue based genomic prognostic signatures in men undergoing active surveillance for prostate cancer.
Publications
Disclaimer: The information presented in this section has been consolidated using AI and machine learning technologies. While every effort has been made to ensure accuracy, errors may occur. If you identify any inaccuracies, please use this link to inform our data team. Your feedback is greatly appreciated and helps us improve the quality of our content.
